Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.49 |
| ▸ | AKT1 | P31749 | 16/20 | 0.49 |
| ▸ | MTOR | P42345 | 13/20 | 0.49 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12313580 | 0.88 | PIK3CA (0.52) | PIK3CAAKT1MTORMAP3K12 | |
| SCHEMBL12488477 | 0.87 | PIK3CA (0.46) | PIK3CAAKT1MTORMAP3K12 | |
| SCHEMBL1497334 | 0.85 | PIK3CA (0.52) | PIK3CAAKT1MTORMAP3K12 | |
| SCHEMBL1497377 | 0.84 | PIK3CA (0.49) | PIK3CAAKT1MTORMAP3K12 | |
| SCHEMBL13196360 | 0.82 | PIK3CA (0.44) | PIK3CAAKT1MTORMAP3K12 | |
| SCHEMBL12849314 | 0.81 | PIK3CA (0.46) | PIK3CAAKT1MTORMAP3K12 | |
| SCHEMBL2397730 | 0.78 | PIK3CA (0.50) | PIK3CAAKT1MTORMAP3K12 | |
| SCHEMBL2393329 | 0.76 | PIK3CA (0.46) | PIK3CAAKT1MTORMAP3K12 | |
| SCHEMBL2397720 | 0.76 | PIK3CA (0.47) | PIK3CAAKT1MTORMAP3K12 | |
| SCHEMBL12849420 | 0.75 | PIK3CA (0.49) | PIK3CAAKT1MTORMAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475375-A2 | PI3 KINASE INHIBITORS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| WO-2011031896-A2 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011031896-A2 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PIK3CA, PIK3CB, PIK3C2B | PIK3CA 1/4885AKT1 27/4885MTOR 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.